IRIS Accounts Production v24.3.2.46 05379955 Board of Directors 1.4.23 31.3.24 31.3.24 false true false false false true false iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh053799552023-03-31053799552024-03-31053799552023-04-012024-03-31053799552022-04-30053799552022-05-012023-03-31053799552023-03-3105379955ns15:EnglandWales2023-04-012024-03-3105379955ns14:PoundSterling2023-04-012024-03-3105379955ns10:Director12023-04-012024-03-3105379955ns10:PrivateLimitedCompanyLtd2023-04-012024-03-3105379955ns10:SmallEntities2023-04-012024-03-3105379955ns10:AuditExempt-NoAccountantsReport2023-04-012024-03-3105379955ns10:SmallCompaniesRegimeForDirectorsReport2023-04-012024-03-3105379955ns10:SmallCompaniesRegimeForAccounts2023-04-012024-03-3105379955ns10:FullAccounts2023-04-012024-03-310537995512023-04-012024-03-3105379955ns10:Director22023-04-012024-03-3105379955ns10:Director32023-04-012024-03-3105379955ns10:RegisteredOffice2023-04-012024-03-3105379955ns5:CurrentFinancialInstruments2024-03-3105379955ns5:CurrentFinancialInstruments2023-03-3105379955ns5:ShareCapital2024-03-3105379955ns5:ShareCapital2023-03-3105379955ns5:RevaluationReserve2024-03-3105379955ns5:RevaluationReserve2023-03-3105379955ns5:RetainedEarningsAccumulatedLosses2024-03-3105379955ns5:RetainedEarningsAccumulatedLosses2023-03-3105379955ns5:NetGoodwill2023-04-012024-03-3105379955ns5:IntangibleAssetsOtherThanGoodwill2023-04-012024-03-3105379955ns5:FurnitureFittings2023-04-012024-03-3105379955ns5:MotorVehicles2023-04-012024-03-3105379955ns5:NetGoodwill2023-03-3105379955ns5:NetGoodwill2024-03-3105379955ns5:NetGoodwill2023-03-3105379955ns5:LandBuildings2023-03-3105379955ns5:PlantMachinery2023-03-3105379955ns5:FurnitureFittings2023-03-3105379955ns5:MotorVehicles2023-03-3105379955ns5:LandBuildings2023-04-012024-03-3105379955ns5:PlantMachinery2023-04-012024-03-3105379955ns5:LandBuildings2024-03-3105379955ns5:PlantMachinery2024-03-3105379955ns5:FurnitureFittings2024-03-3105379955ns5:MotorVehicles2024-03-3105379955ns5:LandBuildings2023-03-3105379955ns5:PlantMachinery2023-03-3105379955ns5:FurnitureFittings2023-03-3105379955ns5:MotorVehicles2023-03-3105379955ns5:WithinOneYearns5:CurrentFinancialInstruments2024-03-3105379955ns5:WithinOneYearns5:CurrentFinancialInstruments2023-03-3105379955ns5:RevaluationReserve2023-03-31
REGISTERED NUMBER: 05379955 (England and Wales)










C B PHARMACIES LIMITED

UNAUDITED FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2024






C B PHARMACIES LIMITED (REGISTERED NUMBER: 05379955)






CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2024




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 4


C B PHARMACIES LIMITED

COMPANY INFORMATION
FOR THE YEAR ENDED 31 MARCH 2024







DIRECTORS: Mr V Duggal
Mr N Duggal
Mrs B Duggal





REGISTERED OFFICE: Cash's Business Centre
1st Floor
228 Widdrington Road
Coventry
West Midlands
CV1 4PB





REGISTERED NUMBER: 05379955 (England and Wales)





ACCOUNTANTS: Shah & Co (Accountants) Ltd
Chartered Certified Accountants
Cash's Business Centre
1st Floor
228 Widdrington Road
Coventry
West Midlands
CV1 4PB

C B PHARMACIES LIMITED (REGISTERED NUMBER: 05379955)

BALANCE SHEET
31 MARCH 2024

31.3.24 31.3.23
Notes £    £   
FIXED ASSETS
Intangible assets 4 53,354 102,604
Tangible assets 5 206,381 207,718
259,735 310,322

CURRENT ASSETS
Stocks 165,787 104,367
Debtors 6 381,337 337,863
Cash at bank and in hand 7,661 211,282
554,785 653,512
CREDITORS
Amounts falling due within one year 7 (395,802 ) (380,547 )
NET CURRENT ASSETS 158,983 272,965
TOTAL ASSETS LESS CURRENT
LIABILITIES

418,718

583,287

PROVISIONS FOR LIABILITIES (2,461 ) (1,200 )
NET ASSETS 416,257 582,087

CAPITAL AND RESERVES
Called up share capital 1,000 1,000
Revaluation reserve 8 48,100 48,100
Retained earnings 367,157 532,987
416,257 582,087

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 March 2024.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 March 2024 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

C B PHARMACIES LIMITED (REGISTERED NUMBER: 05379955)

BALANCE SHEET - continued
31 MARCH 2024


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 5 March 2025 and were signed on its behalf by:





Mrs B Duggal - Director


C B PHARMACIES LIMITED (REGISTERED NUMBER: 05379955)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2024

1. STATUTORY INFORMATION

C B Pharmacies Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

The presentation currency of the financial statements is the Pound Sterling (£).


2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Goodwill
Goodwill, being the amount paid in connection with the acquisition of a business in 2005, is being amortised evenly over its estimated useful life of twenty years.

Intangible assets
Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Fixtures and fittings - 25% on cost
Motor vehicles - 25% on cost

Stocks
Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

C B PHARMACIES LIMITED (REGISTERED NUMBER: 05379955)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MARCH 2024

2. ACCOUNTING POLICIES - continued

Hire purchase and leasing commitments
Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 28 (2023 - 28 ) .

4. INTANGIBLE FIXED ASSETS
Goodwill
£   
COST
At 1 April 2023
and 31 March 2024 985,000
AMORTISATION
At 1 April 2023 882,396
Charge for year 49,250
At 31 March 2024 931,646
NET BOOK VALUE
At 31 March 2024 53,354
At 31 March 2023 102,604

5. TANGIBLE FIXED ASSETS
Fixtures
Freehold Plant and and Motor
property machinery fittings vehicles Totals
£    £    £    £    £   
COST
At 1 April 2023 271,000 5,998 38,455 14,194 329,647
Additions - - 10,000 - 10,000
At 31 March 2024 271,000 5,998 48,455 14,194 339,647
DEPRECIATION
At 1 April 2023 77,208 4,699 34,016 6,006 121,929
Charge for year 5,420 260 3,610 2,047 11,337
At 31 March 2024 82,628 4,959 37,626 8,053 133,266
NET BOOK VALUE
At 31 March 2024 188,372 1,039 10,829 6,141 206,381
At 31 March 2023 193,792 1,299 4,439 8,188 207,718

C B PHARMACIES LIMITED (REGISTERED NUMBER: 05379955)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MARCH 2024

6. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
31.3.24 31.3.23
£    £   
Trade debtors 350,175 164,690
Amounts owed by joint ventures - 14,800
Other debtors 31,162 158,373
381,337 337,863

7. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
31.3.24 31.3.23
£    £   
Bank loans and overdrafts 2,876 -
Trade creditors 369,783 347,193
Taxation and social security 8,746 25,316
Other creditors 14,397 8,038
395,802 380,547

8. RESERVES
Revaluation
reserve
£   
At 1 April 2023
and 31 March 2024 48,100

9. DIRECTORS' ADVANCES, CREDITS AND GUARANTEES

Included in other creditor amount outstanding to Mr N Duggal is nil (2023: £5,512.) Amount is interest free with no set terms of repayment.

10. ULTIMATE CONTROLLING PARTY

The controlling party is Duggal Holdings Limited..

The ultimate controlling parties are Mrs Bholi Duggal, Mr Nitin Duggal and Mr Vipin Duggal by virtue of their majority shareholding in the parent company, Duggal Holdings Limited.